Ultromics showcased FDA-cleared AI-enhanced ultrasound diagnostics detecting cardiac amyloidosis with improved sensitivity and earlier diagnosis at the 2025 scientific session. Meanwhile, a novel pathomics-based machine learning model significantly improved LungPro navigational bronchoscopy accuracy for peripheral lung lesions, addressing critical challenges in pulmonary diagnostics. These innovations illustrate AI’s transformational role in cardiology and pulmonology, promising earlier detection and better patient outcomes in complex diseases.